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BMP10 is highly expressed in the developing heart and plays
essential roles in cardiogenesis. BMP10 deletion in mice results
in embryonic lethality because of impaired cardiac develop-
ment. In adults, BMP10 expression is restricted to the right
atrium, though ventricular hypertrophy is accompanied by
increased BMP10 expression in a rat hypertensionmodel. How-
ever, reports of BMP10 activity in the circulation are inconclu-
sive. In particular, it is not known whether in vivo secreted
BMP10 is active or whether additional factors are required to
achieve its bioactivity. It has been shown that high-affinity bind-
ing of the BMP10 prodomain to the mature ligand inhibits
BMP10 signaling activity in C2C12 cells, and it was proposed
that prodomain-bound BMP10 (pBMP10) complex is latent. In
this study, we demonstrated that the BMP10 prodomain did not
inhibit BMP10 signaling activity in multiple endothelial cells, and
that recombinanthumanpBMP10complex,expressed inmamma-
lian cells and purified under native conditions, was fully active. In
addition,bothBMP10 inhumanplasmaandBMP10secreted from
themouse right atriumwere fully active. Finally,weconfirmed that
active BMP10 secreted frommouse right atriumwas in the prodo-
main-bound form. Our data suggest that circulating BMP10 in
adults is fullyactiveandthat thereportedvascularquiescencefunc-
tion of BMP10 in vivo is due to the direct activity of pBMP10 and
does not require an additional activation step.Moreover, being an
active ligand, recombinant pBMP10 may have therapeutic poten-
tial as an endothelial-selective BMP ligand, in conditions charac-
terized by loss of BMP9/10 signaling.
Bone morphogenetic protein 10 (BMP10)7 plays an impor-
tant role in embryonic cardiac development. During cardiogen-
esis, BMP10 is exclusively expressed in the ventricular trabec-
ular myocardium (1) of mouse embryos at E9.0–13.5, a critical
time for cardiac growth and chamber maturation. The hearts
from BMP10/mice, which die during embryogenesis, show
hypoplastic and thin ventricles with little trabeculation (2).
Overexpression of BMP10 in the postnatal myocardium leads
to smaller hearts within 6 weeks after birth, significant reduc-
tion in ventricular chamber dimensions, thickening of the ven-
tricular wall, and narrowing in the subaortic region (3), indicat-
ing a role for BMP10 in postnatal cardiomyocyte hypertrophic
growth. In adults, BMP10 expression is restricted to the right
atrium (2) and its role in cardiac physiology is not known.How-
ever, increased BMP10 expression was observed in the hyper-
trophied ventricles in a rat model of hypertension (4). Such
restricted and highly regulated expression of BMP10 in adult
hearts strongly suggests that it plays an important role in phys-
iology. To better define the function of BMP10 in vivo, it is
essential to identifywhether the atrium-secretedBMP10 is fully
active or under additional regulation at the protein level.
BMP10 is a member of the transforming growth factor 
(TGF) superfamily. These ligands initiate cellular signaling by
forming a signaling complex comprising two type I and two
type II receptors, both of which are serine/threonine kinases.
Upon signaling complex formation, the type I receptor is acti-
vated due to the phosphorylation by the constitutively active
type II receptor, and phosphorylates the downstream transcrip-
tion factors to control gene expression. There are five type I
receptors: activin receptor-like kinase 1 (ALK1), ALK2, ALK3,
ALK6, and ALK7, and three type II receptors: BMP receptor
type II (BMPR-II), activin receptor type IIA (ActR-IIA), and
ActR-IIB, that mediate BMP signaling. BMP9 and BMP10
belong to the same subgroup of the TGF superfamily based on
amino acid sequence similarities (5), and they are also the only
two known ligands that can specifically activate ALK1. The
ALK1-mediated signaling pathway plays important roles in
normal and tumor angiogenesis and ALK1-Fc (Dalantercept,
ALK1 extracellular domain-Fc fusion protein acting as a ligand
trap) is currently in clinical trials for treating solid tumors (6).
Since ALK1 is almost exclusively expressed on vascular endo-
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thelial cells (7), BMP9 and BMP10 signaling pathways are likely
to play important roles in endothelial cell biology.
TGF/BMP family ligands are synthesized as the pre-pro-
protein and processed into the prodomain and mature growth
factor domain (GFD). Twomajor roles have been described for
the prodomains. First, they interact with fibrillin-1 or other
extracellularmatrix components to target the growth factors to
the specific extracellular space (8). Secondly, the prodomain
can regulate the activity of the mature growth factor by either
conferring latency to the growth factor (9, 10), or not interfer-
ing with growth factor activity (8). For example, prodomain-
bound TGF and myostatin exist in latent forms and require
further mechanisms to activate their signaling activity, such as
the proteolytic cleavage of prodomain by BMP1 (10) or
integrin-dependent activation (11). In contrast, the prodo-
mains of BMP4, 5, and 7 have been shown to bind to their
cognate GFD with very high affinities, but do not affect their
signaling activity (8). Interestingly, using a mouse C2C12 myo-
blast cell-based activity assay with inhibitor of DNA-binding 3
(ID3) gene induction as a readout, the prodomain from BMP10
has been shown to potently inhibit BMP10 activity, and it was
thus proposed that the pBMP10 complex might be similar to
TGF and myostatin in that it is latent and requires additional
factors to achieve activation (8). Apparently consistent with
this observation, BMP10 GFD protein has been detected in
human and mouse sera by ELISA (12) and proteomic
approaches (13). Of note, two independent groups were unable
to detect circulating BMP10 activity in human serum (14, 15),
although BMP10 activity was recently identified in mouse
serum (16). This controversy on circulating BMP10 activity
needs to be resolved since it is difficult to studyBMP10 function
in vivowithout knowingwhether there are additional activation
mechanisms involved.
Extensive studies on BMP9 have been reported in the past
decade. It has been shown that BMP9 is a vascular quiescence
factor, circulating at active concentrations, which inhibits
endothelial cell proliferation and VEGF-induced angiogenesis
(14, 17, 18). Pathogenic mutations in ALK1 which cause hered-
itary hemorrhagic telangiectasia type 2 result in defective
BMP9 signaling (19). In contrast, studies on BMP10 are more
limited, partially because its activity has not been consistently
detected in human serum or plasma. Interestingly, using
BMP10 GFD, in vitro cell biology studies show that BMP10
regulates a similar set of genes to BMP9, and with similar
potency (12, 20). More intriguingly, BMP9 null mice are viable
and it has been proposed that BMP9 and BMP10 can mediate
functionally redundant signals in vivo and BMP10 can substi-
tute BMP9 in postnatal retinal vascular remodeling (12). In
contrast, BMP9 cannot replace BMP10 in cardiac development
even when it is expressed under a BMP10 promoter, indicating
a unique signaling capacity of BMP10 in cardiac development
(16).
To compensate for BMP9 function in BMP9/mice, circu-
lating BMP10 would need to be active. This implies that either
circulating BMP10 is active, or an additional BMP10 activation
mechanism is in place in the BMP9/ mice. Whether the
pBMP10 complex is latent or biologically active is directly rel-
evant to this question. More importantly, if pBMP10 is not
latent, the high level expression of BMP10 in the adult right
atrium might indicate an important physiological role for
BMP10 in the adult heart that is yet to be identified. In addition,
whether pBMP10 is active or not is of significant translational
interest. For example, based on the observation that the prodo-
main is inhibitory, it has been proposed that the BMP10 prodo-
main could be developed into a ligand trap for anti-tumor ther-
apy (8). On the other hand, if pBMP10 itself is active, it might
have therapeutic potential, because administration of the
ALK1-specific ligand, BMP9, has been shown to be beneficial in
preclinical models of pulmonary arterial hypertension (PAH)
(21).
In this report, we showed that the prodomain of BMP10
did not inhibit its activity in multiple endothelial cell lines. In
addition, recombinant human pBMP10 expressed in mamma-
lian cells and purified under native conditions was fully active,
despite pBMP10 being a very stable complex. Furthermore, we
provided evidence that BMP10 derived from endogenous
sources, including cultured mouse right atrium or human
plasma, was fully active on endothelial cells. Finally, we demon-
strated that active BMP10 secreted from the mouse right
atrium was the prodomain-bound complex.
Experimental Procedures
Materials—Anti-BMP9 antibody (MAB3209), anti-BMP10
antibody (MAB2926), BMP10 prodomain (3956-BP-050), anti-
BMP10 propeptide antibody (AF3956), biotinylated anti-
BMP10 propeptide antibody (BAF3956), ALK1-Fc (370-AL),
human BMP10 GFD (2926-BP-025) were all purchased from
R&D Systems, Inc. Anti-phosphoSmad1/5/8 and anti-phos-
phoSmad1/5 antibody were purchased from Cell Signaling
Technology. Anti-ID1 (M085) and anti-ID3 (M100) antibodies
were purchased fromCalBioreagents (SanMateo, CA). HiTrap
Q FF and Superdex 200 10/30 columns were purchased from
GE Healthcare. Human pulmonary artery endothelial cells
(HPAECs) and endothelial growth medium were purchased
from Lonza, UK. Human aortic endothelial cells (HAECs) were
purchased from PromoCell. All other tissue culture medium
were purchased from Life Technologies. All plasmid and RNA
purification kits were purchased from Qiagen. The Gel Filtra-
tion Calibration Kit was purchased from Sigma-Aldrich.
BMP10 Prodomain Inhibition Assay—Because of different
cells having different sensitivities to BMP10, 10 ng/ml of
BMP10 was used to treat C2C12 mouse myoblasts and 1 ng/ml
used for endothelial cells. BMP10 GFDwas pre-incubated with
a 4-fold increased molar ratio of BMP10 prodomain with 0.5%
(v/v) BSA as a carrier protein. The mixture was incubated for
2 h at room temperature before being added dropwise onto
serum-starved cells. Cells were snap-frozen after 1 h of treat-
ment and harvested in SDS-lysis buffer for subsequent immu-
noblot analysis as described previously (22).
Expression and Purification of pBMP10—Human full-length
proBMP10 cDNA was cloned into pCEP4 between XhoI and
BamHI sites and verified by DNA sequencing. Plasmids con-
taining proBMP10were transfected intoHEKEBNA cells using
polyethylenimine as describedpreviously (22).To facilitate pro-
cessing, human full-length furin cDNA, cloned in the same vec-
tor, was co-transfected. To purify pBMP10, 5 liters of condi-
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tioned medium were loaded onto a 100 ml of Q Sepharose
column, pre-equilibrated in 20mMTrisHCl, pH7.4, and bound
proteins were washed and eluted using NaCl gradients from
100 mM to 2 M. After another step of Q-Sepharose high perfor-
mance column separation, fractions containing pBMP10 were
pooled, concentrated in a VivaSpin column, and loaded onto a
HiLoad 16/600 Superdex 200 pg column pre-equilibrated in 20
mM TrisHCl, pH 7.4, 150 mM NaCl. Fractions containing
pBMP10 were dialyzed into 20 mM TrisHCl, pH 7.8, 25 mM
NaCl and further purified on a MonoP 5/200 GL column pre-
equilibrated in 20 mM TrisHCl, pH 7.8. A final Superdex 200
column, pre-equilibrated in 150mMNaCl, 20mMTrisHCl, pH
7.4, was used to separate the pBMP10 from excess prodomain.
Quantification of pBMP10—To compare the activity of in-
house purified pBMP10 with the commercial BMP10 GFD
from R&D Systems, pBMP10 was quantified as the concentra-
tion of mature BMP10 GFD in two steps. In the initial step,
pBMP10was quantified byCoomassie Blue staining on an SDS-
PAGE using BSA as a standard. The result of this initial quan-
tification was used as a guide to prepare the samples in the
second round of quantification using immunoblotting and
commercial BMP10 GFD as a standard. The concentrations of
pBMP10 in all the cell assays described here refer to the con-
centrations of mature GFD in the pBMP10 complex.
Expression and Purification of BMPR-II Extracellular Do-
main (ECD)—Human BMPR2 (NM_001204) ECD, containing
residues 27–150, was cloned into pET39b (Novagen) between
NcoI and NotI sites to generate a construct expressing DsbA-
(His)6-BMPR2 ECD fusion protein. A TEV protease (Tobacco
Etch Virus nuclear inclusion A endopeptidase) cleavage site
was introduced at the N terminus of BMPR2 ECD to facilitate
the cleavage of the fusion protein. The insert was confirmed by
DNA sequencing. The plasmid was transformed into bacterial
strain Rosetta DE3 for protein expression. In brief, cells were
grown at 37 °C until mid-log phase followed by isopropyl--D-
thiogalactoside induction at 25 °C overnight. Total proteins in
the periplasmic compartment were extracted following the
pET SystemManual (Novagen) and applied to a 5 ml of nickel-
nitrilotriacetic acid column (GE Healthcare). Fractions con-
taining the fusion protein were pooled, dialyzed into TBS, and
incubated with His-tagged TEV protease overnight before
being loaded again onto a precharged nickel-nitrilotriacetic
acid column to remove the DsbA tag and TEV protease.
BMPR-II ECD, which was in the flowthrough of the column,
was concentrated and further purified on a S75 gel filtration
chromatography. The final BMPR-II is over 99% pure on an
SDS-PAGE (data not shown).
Human Heart Tissues—Surgical samples of tissues were
obtained from normal hearts not suitable for further transplan-
tation with informed consent from the Papworth Hospital
Research Tissue Bank and experiments performed with local
ethical approval (REC 05/Q0104/142).
Ex Vivo Culture ofMouse Atria—Mouse left atrium (LA) and
right atrium (RA) were dissected from adult C57BL/6 mice
(12–16 weeks old) and either snap-frozen in liquid nitrogen for
RNA extraction or kept in ice-cold PBS for ex vivo cultures. All
animal procedures in this study were carried out according to
HomeOffice regulations and approved by the local animal care
committee. After two additional washing steps with PBS,
pooled fresh atria were transferred into T25 flasks containing
DMEM (0.8 ml medium per atrium, LA and RA from the same
mouse were cultured in parallel) supplemented with Antibiot-
ic-Antimycotic (Life Technologies). The ex vivo culture were
kept at 37 °Cwith 5%CO2. Conditionedmediumwas harvested
between 48 to 72 h and BMP activity in the conditioned
mediumwas evaluated in the endothelial cell signaling assays in
the presence or absence of anti-BMP9 antibody, anti-BMP10
antibody, or ALK1-Fc, respectively.
RNA Extraction and Quantitative PCR (Q-PCR)—Cells were
grown in 6-well plates and serum-restricted overnight prior to
treatments. At the end of time courses, cells were washed with
PBS and snap-frozen on dry ice. Extraction of total RNA was
performed using RNeasy Plus Mini Kit (Qiagen). Total RNA
frommouse atriumwas extracted using RNeasy Fibrous Tissue
Mini Kit (Qiagen). Reverse transcription was carried out fol-
lowing the manufacturer’s instructions (High-Capacity cDNA
Reverse Transcription Kit, Applied Biosystems). Q-PCR reac-
tions were prepared with 4.5 l of diluted cDNA samples and
10.5 l of master mix containing 7.5 l of the SYBR Green
Jumpstart Taq ReadyMix (Sigma-Aldrich), 200 nM of each for-
ward and reverse primers and 10 nM of Rox Reference Dye. The
following forward and reverse primers were used to amplify the
corresponding human genes: ID1: 5-CTGCTCTACGACAT-
GAACGGC, 5-TGACGTGCTGGAGAATCTCCA; -2-mi-
croglobulin (B2M): 5-CTCGCGCTACTCTCTCTTTCT,
5-CATTCTCTGCTGGATGACGTG; BMPR2: 5-CAAATC-
TGTGAGCCCAACAGTCAA, 5-GAGGAAGAATAATCT-
GGATAAGGACCAAT. QuantiTect Q-PCR primers for human
BMP10 (Hs_BMP10_1_SG), mouse BMP9 (Mm_Gdf2_1_SG),
BMP10 (Mm_Bmp10_1_SG) and B2M (Mm_B2m_2_SG) were
purchased from Qiagen. Reactions were amplified on a
StepOnePlusTMthermal cycler (Applied Biosystems) and the
relative expression of target mRNAs was normalized to B2M
using the CT method, expressed as the fold-change relative
to control samples, and shown asmean S.E. where applicable.
Fractionation of ConditionedMedium fromRA—ASuperdex
200 10/300 GL column was equilibrated in PBS and proteins of
known molecular weights from the Gel Filtration Calibration
Kit were fractionated to obtain the elution volumes for proteins
of different sizes. Conditioned medium from RA or diluted in-
house purified pBMP10 were passed though the same column
under identical conditions, and the eluate was collected as
250-l fractions after the void volume. Every second fraction
was assessed for BMP10-activity using BMP-responsive ele-
ment (BRE)-Luciferase Assay in C2C12 cells as described pre-
viously (22) with the followingmodifications: C2C12 cells were
seeded in 24-well plate at 3  104 cells/well. All wells were
transfected with 400 ng of plasmid containing BRE-luciferase
(kind gift from Professor P. ten Dijke), 40 ng of Renilla lucifer-
ase, and 5 ng of pcDNA3:hALK1 per well. Cells were quiesced
for 16 h in serum-free DMEM and then treated in triplicate for
6 h with an appropriate dilution of each fraction. Firefly and
Renilla luciferase activities were measured and analyzed as
described previously.
pBMP10 ELISA—A high binding 96-well ELISA plate was
coatedwith anti-BMP10monoclonal antibody (2g/ml) in PBS
Prodomain-bound BMP10 Is Active
2956 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 291•NUMBER 6•FEBRUARY 5, 2016
at 4 °C overnight. After washing with PBS, wells were blocked
with 1% BSA in PBS for 2 h, washed with PBS, and 100 l of
undiluted fractions were applied in duplicate. After 2 h of incu-
bation at room temperature, wells were washed again and
probed with biotinylated anti-BMP10 propeptide antibody (0.4
g/ml) for 2 h at room temperature. After further washing,
ExtraAvidin-Alkaline Phosphatase conjugate (Sigma Aldrich
E2636, 1:400 in 1% BSA/PBS) was applied. Two hours later,
wells were washed and pNPP solution (Sigma Aldrich NP2640)
was added. Development was carried out in the dark at 37 °C
with readings taken every 15 min at 405 nm in a Bio-Rad 680
microplate reader until the signals were fully developed.
Antibody Neutralization Assay—Based on initial titrations
(data not shown), 1% (v/v) freshly frozen human plasma or 0.4%
(v/v) mouse RA-conditional medium was used in the assays.
Stimuli were mixed with neutralizing reagents or PBS as con-
trols and pre-incubated for 1 h at room temperature to allow
neutralization. The solutionwas added dropwise ontoHPAECs
in 6-well dishes, and cells were harvested after 1 h of treatment.
RNA extraction, reverse transcription, and Q-PCR reaction
were carried out as described above. The final concentrations of
ALK1-Fc in all neutralizing experiments were 2.5g/ml. In the
plasma neutralizing experiment, the final concentrations of
anti-BMP9 antibody were 15g/ml () or 20g/ml (), and
anti-BMP10 antibody was applied at 15 g/ml. In the experi-
ment of neutralizing BMP activities from RA-conditioned
medium, final concentrations of anti-BMP9 and anti-BMP10
antibodies were both at 20 g/ml, respectively.
Statistical Analysis—Data are presented as mean  S.E.
Paired t test was used for comparison between two groups, and
for multiple group comparisons, one-way ANOVA followed by
Tukey’s or Dunnett’s post test was used when appropriate and
as specified in the figure legends. p 0.05 was considered sta-
tistically significant. All the analyses were performed using
GraphPad Prism.
Results
BMP10 Prodomain Inhibits BMP10 Activity in C2C12
Cells—Because the previously reported prodomain inhibition of
BMP10was carried out inC2C12 cells (8), wewished to confirm
this observation prior to studies in endothelial cells. Instead of
using 50 ng/ml treatment for 6 h and ID3 gene induction as a
readout (8), we chose to monitor the phosphorylation of
Smad1/5 after 1 h of treatment since this event is upstream of
ID gene induction and directly reflects the receptor activation
by BMP10 with minimum interference from any downstream
events or other signaling pathways. We also carried out immu-
noblotting for ID1 and ID3 proteins in the same cell lysates to
establishwhether the Smad1/5 phosphorylation correlateswith
the induction of ID proteins.We initially analyzed the dose-de-
pendent response to the BMP10 GFD to define the concentra-
tion to use in the prodomain inhibition assay (Fig. 1A). We
could detect Smad1/5 phosphorylation from 1 ng/ml BMP10
GFD, with robust signal detected at 10 ng/ml. No change in the
total Smad1 level was observed following BMP10 treatment.
Immunoblotting with anti-ID1 and anti-ID3 antibodies con-
firmed that this dose-dependent Smad1/5 phosphorylation is
correlated with an increase in ID protein levels (Fig. 1A). We
therefore chose to use 10 ng/ml BMP10 GFD for the prodo-
main inhibition assay. BMP10 GFD was pre-incubated with
increasing amounts of the BMP10 prodomain as indicated in
Fig. 1B before being applied to the serum-starved C2C12
cells. In agreement with published results, even using a dif-
ferent assay, we could indeed observe the inhibition by the
prodomain, but only at 64-fold molar excess (Fig. 1B).
Because it is not known whether BMP10 signaling in C2C12
FIGURE 1. BMP10 prodomain inhibits BMP10 activity in C2C12 cells. A,
titration of BMP10 GFD activity in C2C12 cells. Serum-starved C2C12 cells
were treated with BMP10 GFD at increasing concentrations for 1 h, and the
phosphorylation of Smad1/5 and the induction of ID1 and ID3 proteins were
measured by immunoblotting analysis. Total Smad1 was used as a loading
control. B, prodomain inhibition assay in C2C12 cells. BMP10 GFD was pre-
incubated with the prodomain (molar ratio BMP10 GFD to prodomain, 1:0,
1:1, 1:4, 1:16, and 1:64) before applying to the serum-starved C2C12 cells for
1 h. Ratio 0:64 indicates the same amount of prodomain as in 1:64, but in the
absence of BMP10 GFD. The remaining activity was measured by phosphor-
ylationof Smad1/5 using immunoblotting; total Smad1was used as a loading
control. One representative blot from four repeats is shown. Below, using
densitometry analysis (Image J), relative phosphorylation of Smad1/5 were
corrected to total Smad1 and normalized to the sample treated with BMP10
onlywithout the prodomain (1:0). The fold changes are expressed asmean
S.E. n	 4; ****, p 0.0001; n.s., not significant. One-way ANOVA, Dunnett’s
post test.
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cells represents any in vivo situation, the impact of this
observation is still not fully clear.
BMP10 Prodomain Does Not Inhibit BMP10 Activity in
Endothelial Cell Lines—Because endothelial cells are the most
relevant target cells to mediate BMP10 functions in adults, we
testedwhether the prodomain could inhibit BMP10GFD activ-
ity in several types of endothelial cells, including HPAECs,
HAECs, and HMEC-1. To establish the concentration of
BMP10 GFD to use for the inhibition assay, we assessed the
concentration-responses to the BMP10 GFD in HPAECs and
HAECs. As shown in Fig. 2A, in both HPAECs and HAECs,
Smad1/5 phosphorylation and ID1, ID3 protein inductionwere
detected in response to BMP10GFDat concentrations as low as
0.1 ng/mlwith robust signals at 1 ng/ml. Again no changeswere
observed in the levels of total Smad1 protein following BMP10
treatment.We chose to use 1 ng/ml of BMP10GFD and carried
out the prodomain inhibition assay using the samemolar excess
of prodomain as described above in the C2C12 assays. In all
three types of endothelial cells, we could not detect any inhibi-
tion of BMP10-mediated Smad1/5 phosphorylation by the
prodomain even when applied at 64-fold molar excess (Fig. 2,
B–D). It is difficult to envisage in any in vivo situations that
there would be more than 64-fold excess of BMP10 prodomain
present alongside its GFD, we therefore conclude that the
prodomain does not inhibit BMP10 activity in endothelial cells.
Generation of Human pBMP10 Complex—Having demon-
strated that the prodomain does not inhibit BMP10 activities in
vascular endothelial cells, we next asked whether pBMP10
complex is latent or active on these endothelial cells. To test
this, we generated recombinant human pBMP10 using a mam-
malian expression system. Similar to all other TGF family
members, BMP10 is synthesized as a pre-propeptide compris-
ing a signal peptide, prodomain, andmature BMP10GFDat the
C terminus. Upon secretion, the signal peptide is removed and
prodomain cleaved by furin-like proprotein convertase in the
Golgi apparatus to generate the active growth factor (Fig. 3A). It
has been shown that when recombinant BMP9 or BMP7
expressed from mammalian cells is fractionated on a non-re-
ducing SDS-PAGE, both dimeric and monomeric BMP GFD
can be detected (22, 23).We found this was also true for BMP10
FIGURE2.BMP10prodomaindoesnot inhibitBMP10activity inendothelial cell lines.A, titrationof BMP10GFDactivities inHPAECs (left) andHAECs (right).
Increasing concentrations of BMP10 GFD as indicated were used to treat the serum-starved cells. After 1 h treatment, cells were harvested and the phosphor-
ylationof Smad1/5 and the inductionof ID1 and ID3proteinswere analyzedusing immunoblotting.B, BMP10GFDwaspre-incubatedwith increasing amounts
of BMP10 prodomain in samemolar ratio as in Fig. 1B before applying to serum-starved endothelial cells in (B) HPAECs, (C) HAECs, and (D) HMEC-1. Remaining
activity of BMP10wasmeasured by phosphorylation of Smad1/5with total Smad1 as a loading control. One representative blot from four repeats is shown for
all experiments. Prodomain inhibitions were quantified and analyzed as in Fig. 1B and shown below.
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(data not shown). The purified pBMP10 complex eluted under
a single peak on a gel filtration column (Fig. 3B) and SDS-PAGE
fractionation of the peak fraction showed pBMP10 complex
was over 95% pure (Fig. 3C). Both monomeric and dimeric
BMP10 GFD could be seen on a non-reducing SDS-PAGE,
which are very likely to be the covalently-linked (D-form) and
non-covalently linked (M-form) BMP10 dimer, as we have pre-
viously characterized for BMP9 (22), because both D- and
M-forms can form a complex with the prodomain and co-elute
on the size exclusion column (Fig. 3B). The identities of BMP10
GFD and its prodomain were confirmed by mass spectrometry
in-gel trypsin digestion and peptide mapping (data not shown),
as well as by immunoblotting for BMP10 GFD and its prodo-
main (Fig. 3,D and E). Protein N-terminal sequencing revealed
amino acid residues SPIMN for prodomain and NAKGN for
both BMP10 D- and M-forms, confirming the correct pro-
cessing of the pBMP10 complex.
Prodomain-bound BMP10 Is a Highly Stable Complex—The
prodomain has been shown to bind to its cognate BMP at a
site that overlaps with the type II receptor binding surface
(24), suggesting that the prodomain needs to be displaced to
allow signaling complex formation. We tested when purified
pBMP10 was subjected to different chemical conditions that
are known to weaken protein-protein interactions, whether the
prodomain would dissociate from BMP10 GFD. Guanidine
hydrochloride (GuHCl) is a strong chaotropic agent that can
interrupt hydrophobic interactions within proteins and protein
complexes. It has been used extensively to denature proteins in
protein unfolding studies. Some proteins start to unfold at 1 M
GuHCl (25). In addition, high salt concentrations are known to
affect the stabilities of protein complexes by reducing the elec-
trostatic forces in protein-protein interactions (26, 27). To test
whether the BMP10 prodomain and GFD in the pBMP10 com-
plex would dissociate in the presence of low concentrations of
chaotropic agent or high concentrations of salt, semi-purified
recombinant pBMP10 (with excess prodomain) was pre-incu-
bated in either TBS alone, or TBSwith final concentrations of 1
M GuHCl or 1 MNaCl before being loaded onto an S200 10/300
gel filtration column pre-equilibrated in the same buffer. As
shown in Fig. 4, pBMP10 is a highly stable complex, which did
not dissociate and was eluted under a single peak in either 1 M
NaCl (Fig. 4B, peak X) or 1 MGuHCl solutions (Fig. 4C, peak X).
Excess prodomain was eluted under a separate peak (peak Y in
Fig. 4, A–C), providing further support that prodomain was
FIGURE 3. Generation of recombinant human pBMP10. A, schematic diagram of BMP10 production and processing. B, FPLC chromatography gel filtration
trace of purified pBMP10. C, purified pBMP10 shown as the peak fraction from the gel filtration in B on a non-reducing SDS-PAGE. A single asterisk denotes a
nonspecific protein. D, both D- and M-forms of BMP10 GFD could be detected by monoclonal anti-BMP10 antibody. E, prodomain can be detected by
anti-BMP10 prodomain antibody. BMP10 GFD from R&D Systems was used as a positive control in D and negative control in E.
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indeed in a complex with BMP10 GFD under peak X in each
condition. To further demonstrate that the interaction between
BMP10 and the prodomainwas specific, we employed a control
protein with a similar molecular weight to BMP10 GFD dimer
(carbonic anhydrase, 24 kDa), which does not interact with
BMP10 or its prodomain. Carbonic anhydrase was pre-mixed
with pBMP10 before injection in each run. In all three buffer
conditions, the control protein was eluted under a separate
peak corresponding to a lower molecular weight (peak Z in Fig.
4, A–C).
Prodomain-boundBMP10 IsNot Latent and Is Fully Active in
Multiple Endothelial Cell Lines—To test whether pBMP10 is
active in endothelial cells, we quantified our in-house generated
recombinant pBMP10 by immunoblotting using an anti-
BMP10 antibody, with commercial BMP10 GFD as a standard
(data not shown). We then treated HPAECs and HAECs with
increasing concentrations of pBMP10, alongside BMP10 GFD
as a control, and monitored the canonical Smad1/5 phosphor-
ylation. As shown in Fig. 5,A and B, in both types of endothelial
cells pBMP10 is slightly less active at very low concentrations,
as Smad1/5 phosphorylation can be detected when cells were
treated with BMP10 GFD at 0.1 ng/ml, but not with all the
pBMP10 batches. However, when applied at 1 ng/ml concen-
tration, pBMP10 induced robust Smad1/5 phosphorylation,
comparablewithBMP10GFD.We further compared induction
of ID1 and BMPR2 gene expression by BMP10 GFD and
pBMP10 inHPAECs (Fig. 5C). These are twowell-documented
target genes of BMP9- and BMP10-signaling in endothelial
cells. Consistent with the Smad1/5 phosphorylation results, at
very low concentrations (0.33 ng/ml for ID1 and 1 ng/ml for
BMPR2 gene inductions), pBMP10 was slightly less active than
BMP10 GFD, but this difference disappeared when a slightly
higher concentration of ligand was applied. These results sup-
port the conclusion that pBMP10 complex is an active ligand in
endothelial cells.
BMPR-II ECDCanRelease BMP10 from pBMP10Complex—
Because the pBMP10 complex is active on endothelial cells, one
possibility is that the contact of pBMP10with the receptors can
release BMP10 GFD from the complex. It has been shown for
BMP7 and BMP9 that the prodomain competes for the binding
of the type II receptors, not the type I receptors (24, 28). We
therefore testedwhether BMPR-II ECDcan displace the prodo-
main from the pBMP10 complex. Using native PAGE analysis,
we found that the pBMP10 complex migrated as three bands
(Fig. 6A, 1:0). Immunoblots of the proteins eluted from the
three bands (Fig. 6B) revealed their identities as BMP10 GFD
alone (band 1), pBMP10 complex (band 2), and prodomain
alone (band 3). Interestingly, when increasing amounts of
FIGURE4.Prodomain-boundBMP10 is ahighly stable complex.Analytical gel filtration analysis of semi-purifiedpBMP10 in TBS (A), TBSwithNaCl at 1M final
concentration (B) or TBS with 1 M GuHCl (C). pBMP10 was pre-incubated in each buffer for 30 min before being loaded onto a Superdex S200 10/300
size-exclusion column pre-equilibrated in the same buffer. A control protein carbonic anhydrase (24 kDa) that does not interact with either BMP10 GFD or its
prodomainwas added to the pBMP10 before loading. Blue dextran (2000 kDa, black arrow) was run separately in each buffer to indicate the void volume. Note
theprotein peaks shifted slightly between the runs, potentially due toproteins interactingwith the columnmatrix differently in different buffer systems. Points
1–11 on the traces correspond to consecutive fractions, which were run in lanes 1–11 of immunoblotting analyses probed with either anti-BMP10 prodomain
or anti-BMP10antibodies.PeaksXandYwereTCAprecipitated, ranonanon-reducingSDS-PAGEandCoomassieBlue stained to reveal the identityof thepeaks.
Peak Z is carbonic anhydrase.
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BMPR-II ECD were added, pBMP10 complex decreased in a
dose-dependentmanner (Fig. 6A, black arrow). To confirm that
this was not due to the variation in the amount of protein
loaded onto the native PAGE, we repeated the experiment four
times and plotted the ratio of pBMP10 : prodomain (Fig. 6C).
We observed a reduction of pBMP10 complex when BMPR-II
ECD was present at 2-fold excess, and this reduction reached
statistical significance at 4:1 ratio of BMPR-II ECD : prodo-
main, confirming that BMP type II receptor can indeed com-
pete for prodomain binding and release the BMP10 GFD from
the pBMP10 complex in vitro.
BMP10 Derived From Atrium or Plasma Is Fully Active—
Having shown that recombinant pBMP10 complex is fully active,
we hypothesized that RA-secretedBMP10 is also active andnot in
the latent form.We first of all confirmed the specific expression of
BMP10 in adult heart tissue. In human adult heart, no BMP10
expression could be detected in left or right ventricles (Fig. 7A).
BMP10expression couldbedetected in theLA, but the expression
level was nearly 10 times higher in theRA.We then confirmed the
BMP10 expression in left and right atria from adult mice, and
found that the expression level of BMP10 in the RA was about
170-fold higher than that in the LA (Fig. 7B).
FIGURE 5.Prodomain-boundBMP10 is active in endothelial cells.A and B,phosphorylation of Smad1/5 in HPAECs (A) andHAECs (B) treatedwith 0.1 ng/ml,
0.33 ng/ml, and 1 ng/ml of BMP10 GFD or three independent preparations of pBMP10 for 1 h, detected by Smad1/5 phosphorylation in immunoblotting
analysis; total Smad1wasusedas a loadingcontrol. The concentrationsofpBMP10 inall the cell assays refer to the concentrationsofmatureGFD in thepBMP10
complex. Relative phosphorylation of Smad1/5 upon treatment was measured using densitometry, corrected to total Smad1 and normalized to 0.1 ng/ml
BMP10GFD treatment condition andplottedon the right.C, inductionof ID1 and BMPR2mRNAexpressionby recombinant pBMP10, comparedwith BMP9 and
BMP10 GFD. HPAECswere treatedwith the ligands at indicated concentrations for 8 h before samples were harvested for RNA extraction and qPCR analysis as
described in “Experimental Procedures.” n	 3; *, p 0.05; n.s., not significant; paired t test.
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To ascertain whether the RA-secreted BMP10 is active or
not, we tested BMP10 activity secreted from ex vivo cultured
mouse RA, with LA cultured alongside as a negative control. As
shown in Fig. 7C, strong ID1 gene induction activities could be
detected in HPAECs treated with conditioned medium from
the RA, but not in that from the LA. This ID1-induction activity
was completely inhibited by ALK1-Fc, partially inhibited by
anti-BMP10 antibody, but not at all by anti-BMP9 antibody
(Fig. 7D). Control experiments showed that anti-BMP9 anti-
body could effectively neutralize BMP9 activity but it could not
inhibit either BMP10 or pBMP10 activity, whereas ALK1-Fc
could block both the BMP9 andBMP10 signaling activities (Fig.
7E). Although we could not detect any neutralizing activity for
BMP10 GFD or pBMP10 in this assay using the commercially
available anti-BMP10 antibodies (data not shown), we could
observe partial inhibition using anti-BMP10 antibody when we
used a smaller volume of the RA-conditioned medium in the
signaling assay (Fig. 7D). These data strongly suggested that the
ID1 gene-induction activity in the RA-conditioned medium
was indeed due to BMP10, not BMP9. This is in agreementwith
previous reports that BMP9 is mostly expressed in the liver and
no BMP9 expressionwas detected in the heart (14, 29). Next we
investigated whether we could detect any BMP10 activity in
human plasma (Fig. 7F). Freshly frozen plasma (at 1% final con-
centration) potently induced ID1 gene expression in HPAECs,
and this activity was completely inhibited byALK1-Fc, suggest-
ing that all the ID1-induction activity in 1% plasma was attrib-
uted to BMP9 and BMP10. While most of this ID1-induction
activity was inhibited by anti-BMP9 antibody, the remaining
activity could not be inhibited by a higher concentration of
anti-BMP9 antibody, but was inhibited effectively by either
anti-BMP10 antibody or ALK1-Fc, indicating that this remain-
ing ID1 gene induction activity was due to BMP10.
RA-derived Active BMP10 Exists as the pBMP10 Complex—
Next we questioned whether the BMP10 activity from natural
source was in the form of BMP10 GFD or pBMP10 complex.
Plasma contains both BMP9 and BMP10, which are difficult to
separate, whereas conditioned medium from the RA contains
only BMP10. Therefore, we chose to fractionate the RA-condi-
tioned medium using S200 size-exclusion chromatography to
separate proteins of different sizes. We then monitored the
BMP activities from the fractions using BRE-luciferase activity
assays in ALK1-transfected C2C12 cells, since the fractions
could only contain BMP10 activity (Fig. 7D). As shown in Fig. 8,
a control experiment showed that when recombinant pBMP10
was applied to the gel filtration column, BRE-luciferase activity
could be detected in fractions with a peak at around 12.5 ml,
corresponding to a protein or protein complexwith amolecular
weight of 138–155 kDa according to the calibration standards.
The expectedmolecular weight of a dimeric pBMP10 complex,
calculated fromamino acid compositions, is 92 kDa. The higher
than expected molecular weight could be due to glycosylation
as there are two predicted glycosylation sites in each prodo-
main, hence four glycosylation sites in the dimeric pBMP10
complex. In addition, it has recently been shown by electron
microscopy that pBMP9 complex (and pBMP7 complex)
adopts an elongated open conformation (28). If pBMP10 com-
plex adopts a similar open conformation, it will also contribute
to the apparent higher molecular weight on a size exclusion
column. When RA-conditioned medium was applied to the
FIGURE 6.BMPR-II ECD can release BMP10GFD from the pBMP10 complex. A and B, interaction between BMPR-II ECD and pBMP10was investigated using
native PAGE. Purified pBMP10 complex was run on a 10% native PAGE (A) either alone (1:0), or with increasing amounts of BMPR-II ECD (molar ratio of
pBMP10:BMPR-II ECD, 1:1, 1:2, and 1:4). 0:1 refers to BMPR-II alone control. Prodomain-bound BMP10 complex was separated into three bands on the native
PAGE. These three bands were excised from the native PAGE, run in parallel on non-reducing SDS-PAGE, and probed with either anti-BMP10 antibody or
anti-BMP10 prodomain antibody (B). Band 1, which ran as a smeared band and stayed in the stacking gel, contains only BMP10 GFD, consistent with the PI of
BMP10 GFD being 8.67. Band 3 contained only the prodomain (PI 	 4.54) and ran fastest on the SDS-PAGE. Band 2 contained both BMP10 GFD and the
prodomain, hence is the pBMP10 complex. The arrow in A points to the decrease in the pBMP10 complex upon adding increasing amounts of BMPR-II ECD. A
single asterisk in B denotes either a nonspecific protein in the protein prep or a differentially processed BMP10 prodomain. C, changes of pBMP10 complex in
Awere quantified as the ratio of the pBMP10 complex/prodomain alone to normalize for the loading. n	 4, one-way ANOVA, Dunnett’s post test. **, p 0.01.
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S200 column under identical conditions, peak BRE-luciferase
activity was detected at around 12.7 ml, indicating that BMP10
activity in RA-conditioned medium was due to a protein or
protein complex with a similar molecular weight to the
pBMP10 complex.
To confirm that BMP10 activity in the RA-conditioned
medium was indeed in the form of pBMP10 complex, we sub-
jected the fractions fromRA-conditionedmedium gel filtration
to a pBMP10-specific ELISA assay, using anti-BMP10 mono-
clonal antibody as the capture antibody, and biotinylated anti-
prodomain antibody as the detecting antibody. This ELISA will
only show positive signals in fractions containing pBMP10
complex. As shown in Fig. 8, the profile of ELISA signals mir-
rored that of the BRE-luciferase activities, with the peaks
aligned perfectly, supporting the hypothesis that active BMP10
secreted from mouse RA was indeed in the prodomain-bound
complex.
Discussion
In this study, we demonstrated that exogenous addition of
the BMP10 prodomain did not inhibit BMP10 GFD activity in
three endothelial cell lines, including primary endothelial cells.
Using the recombinant human pBMP10 complex overex-
pressed in mammalian cells and purified under native condi-
tions, we showed that pBMP10, contrary to being latent, was
fully active in inducing Smad1/5 phosphorylation and the
ID1 and BMPR2 gene expression in multiple endothelial cell
lines. In addition, we have demonstrated BMP10 activity in
freshly frozen human plasma. Finally, we show evidence that
FIGURE 7. BMP10 derived from atrium or plasma is fully active. A, BMP10 mRNA expression in human heart tissues. n	 3. **, p 0.01; one-way ANOVA,
Tukey’s post test.B, BMP10mRNAexpression inmouseheart tissues.BMP10 expression is significantly higher in RA than LA inmouse.n	4, paired t test; **,p
0.01; C, BMP activity could be detected in the conditioned medium of cultured mouse RA. Conditioned medium from LA or RA was applied to serum-starved
HPAECs (both at 5% v/v), and the BMP activity was measured by the induction of ID1 gene expression. No BMP activity can be detected from LA-conditioned
medium (LA CM), while significant level of ID1 gene induction activity can be detected in the RA-conditioned medium (RA CM). n 	 3, * p  0.05; n.s., not
significant. One-way ANOVA, Tukey’s post test; D, identification of BMP activity in RA CM. The ID1-induction activity from RA CM (0.4% v/v) could not be
inhibited by anti-BMP9 antibody (at 20g/ml), but can be partially inhibited by anti-BMP10 antibody (at 20g/ml), and very effectively inhibited by ALK1-Fc
(at 2.5g/ml).n	3, *,p0.05;n.s., not significant.One-wayANOVA,Dunnett’s post test; E, control experiments showed that anti-BMP9antibody (at 10g/ml)
could specifically neutralize BMP9 activity very effectively, but not the activity of BMP10 or pBMP10,whereas ALK1-Fc (at 2.5g/ml) can inhibit both BMP9 and
BMP10 activity very effectively. The concentrations of BMP9, BMP10, and pBMP10 used in this assay were all 1 ng/ml. n	 3, one-way ANOVA for each BMP
ligandgroup,Dunnett’s post test, **,p0.01; *,p0.05;n.s., not significant; F, BMP10 activity canbedetected inhumanplasma. Freshly frozenhumanplasma
was used to treat serum-starvedHPAECs (1% v/v final concentration), andBMPactivitywasmeasuredby ID1gene induction. All the ID1-induction activity from
1%plasma can be completely inhibited by ALK1-Fc (at 2.5g/ml) alone, suggesting that all the ID1-gene induction activity in 1%plasmawas due to BMP9 and
BMP10. While most of this activity can be inhibited by anti-BMP9 antibody (at 15g/ml), the residual ID1-induction activity cannot be inhibited by additional
amounts of anti-BMP9 antibody (at 20 g/ml). It can be only inhibited by either anti-BMP10 antibody (at 15 g/ml) or ALK1-Fc (at 2.5 g/ml), suggesting the
residual ID1-induction activity is due to BMP10. n	 3, one-way ANOVA, Dunnett’s post test. *, p 0.05; #, p 0.05; ##, p 0.01; n.s., not significant.
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the right atrium secretes active BMP10 as the prodomain-
bound complex.
Differential expression of BMP receptors, especially the high
affinity receptors, on the cell surface can confer different sensi-
tivity to diverse BMPs. For example, the high affinity type I
receptors for BMP4 and BMP9 are ALK3 and ALK1 respec-
tively. Relative to smoothmuscle cells (SMCs), endothelial cells
express higher levels of ALK1 and much lower levels of ALK3
(30, 31). This would predict that BMP9 signals preferentially in
endothelial cells and BMP4 in SMCs. Indeed, a recent publica-
tion reports a side-by-side comparison between BMP4 and
BMP9 signaling in HPAECs and pulmonary artery SMCs (21).
BMP9 induced strong Smad1/5 phosphorylation in endothelial
cells at concentrations as low as 0.1 ng/ml, but only induced
weak Smad1/5 phosphorylation at 1 and 10 ng/ml in SMCs.
Similarly, Smad1/5 phosphorylation induced by BMP4 treat-
ment can be detected at 0.1 ng/ml in SMCs, but not at 100
ng/ml in endothelial cells (21). Using physiologically relevant
cells to address the function of a specific BMP allows the BMP
ligand to be tested at close to physiological concentrations, and
in the correct receptor context. Endothelial cells are the most
physiologically relevant cell types for investigating BMP9/10
function since BMP9/10 have been proposed to act as vascular
quiescence factors that signal via ALK1 in endothelial cells (20,
32). In addition, the localized expression and secretion of
BMP10 from the right atrium means that the pulmonary vas-
cular endothelium is likely a major downstream target for this
ligand. Hence, we focused on using endothelial cells to investi-
gate BMP10 activity. Previous reports showing that the prodo-
main inhibits BMP10 activity were conducted in C2C12 cells
without ALK1 transfection. Although we have recapitulated
this result in the present study, we clearly demonstrated that
this was not the case in endothelial cells. Under physiological
conditions, the roles and signaling pathways of BMP10 in
embryonic developmentmay be different from that in adult life.
It was elegantly shown that BMP10 has two distinct functions
during development; one is to support early vascular develop-
ment, which can be substituted by BMP9, the other is to regu-
late heart development that cannot be substituted by BMP9
(16). It is tempting to speculate that BMP10 may act on a dif-
ferent cell type to exert its role in heart development, and that
this is likely to be mediated through a different set of receptor
complexes. Thus the inhibitory role of the prodomain on
BMP10 activity may still hold true in other cellular contexts.
Until now, the reports on whether BMP10 circulates and is
active have been inconclusive. On the one hand, circulating
BMP10 frommouse and human sera can be detected by ELISA
(12) as well as by pull-down coupled with proteomics (13), but
its activity has not been detected in two previous reports (15,
17). Again, this absence of detectable BMP10 activity in those
reports could be due to the cell types used for the activity assays.
In one report, Herrera et al. found that in C2C12 reporter cells,
the lower sensitivity for BMP9 was 0.1 ng/ml and for BMP10
was 1 ng/ml (15). Clearly this C2C12 assay would not be able to
detect BMP10 activity if it is present in the plasma at concen-
trations lower than 1 ng/ml, and we have shown here that
pBMP10 complex is active at 0.33 ng/ml in inducing Smad1/5
phosphorylation in endothelial cells. In another study, NIH-
3T3 cells were transfectedwith ALK1 to enhance their sensitiv-
ity to BMP9 and BMP10. Although anti-BMP9 antibody abol-
ished the activity of recombinant BMP9, it did not completely
inhibit the serum-induced BRE-stimulating activity (17).
Unfortunately, neither anti-BMP10 antibody nor ALK1-Fc was
tested to further inhibit the residual BRE-luciferase activity.
Consistent with this latter study, we observed that the BMP
activity in human plasmameasured by ID1mRNA induction in
HPAECs was largely contributed by circulating BMP9, which
could be effectively inhibited by an anti-BMP9 antibody. In
addition, we demonstrated that the residual activity was only
inhibited by anti-BMP10 antibody or by ALK1-Fc, not by fur-
ther addition of anti-BMP9 antibody. By monitoring Smad6
induction in human umbilical vein endothelial cells, Chen et al.
detected BMP10 activity in mouse serum (16). To our knowl-
edge this is the first time that the presence of circulating BMP10
activity in human plasma has been demonstrated.
Our finding that RA-secreted BMP10 is active on endothelial
cells implies that BMP10 may play an active hitherto unrecog-
nized role in adult life. BMP9 and BMP10 are the only two
known ligands activating the ALK1-mediated pathways and
control the expression of a similar set of genes (12, 20). They
signal redundantly in vivo and BMP10 can substitute BMP9 for
postnatal retinal vascular remodeling in BMP9/ mice (12,
16). BMP9 is a vascular quiescence factor in the vascular endo-
thelium (17) and BMP10 has been shown to mediate flow-de-
pendent arterial quiescence in zebrafish (32). Since RA-se-
creted BMP10 will first enter the right ventricle and then
pulmonary circulation, BMP10 may contribute to the vascular
quiescence in the pulmonary endothelium. It is interesting to
note that mutations in the BMPR2 gene, which encodes the
major type II receptor for the large family of BMPs, is the most
common genetic cause of PAH, a disease characterized by the
FIGURE 8. Right-atrium-secreted active BMP10 is in the prodomain-
bound form. Proteins from RA-conditioned medium were separated by gel
filtration chromatography, and the BMP activities in the fractions were mea-
sured using the BRE-luciferase assay as described in “Experimental Proce-
dures.” The relative BRE-luciferase activities in the fractions were plotted
against their elutionvolumes (black linewith circle symbols). The sameprocess
was repeated with diluted, purified recombinant human pBMP10, and the
relative BMP activities in the fractions were also measured and plotted (gray
linewith square symbols). In addition, a pBMP10-specific ELISAwas carried out
to measure the proteins in the fractions from RA-conditioned medium gel
filtration. Data were presented as optical densities (absorbance at 405 nm,
right axis, dotted line with triangular symbols). Proteins fromGel Filtration Cal-
ibration Kit were run under identical conditions, and arrows below showed
the elution volumes of the protein standards.
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extensive remodeling of pulmonary arteries, right ventricular
hypertrophy and heart failure (33). Most importantly, selective
enhancement of the endothelial BMPR-II pathway with BMP9
can reverse established PAH in several animal models (21). It
would be interesting to test whether BMP10-mediated signal-
ing plays a protective role in the pulmonary circulation, and
since pBMP10 complex is an active and redundant ligand to
BMP9, pBMP10 could also have therapeutic potential for treat-
ing PAH.
Questions remain regarding the role of the prodomain in
regulating BMP signaling. For example, BMP9 and BMP10
share 64% sequence identity in the GFD, but only 29% in their
prodomains. It is possible that this sequence variation confers
temporal and spatial signaling specificity to BMP9 and BMP10.
In addition, quantitative ELISA binding measurements for
BMP7 and BMP9 show that the prodomain has little effect on
the affinities for type I receptor, but can alter both the EC50 and
the selectivity of type II receptor binding to BMPs (24, 28). Such
selectivity of different type II receptors, conferred by the prodo-
main, is yet to be demonstrated in cell signaling and functional
assays. It is interesting to note that, similar to our observation
that the prodomain can inhibit BMP10 activities in C2C12 cells
but not in endothelial cells and that prodomain-bound BMP10
is fully active, it has recently been shown that the prodomain of
BMP9, albeit at a large molar excess, can also inhibit BMP9
activity in C2C12 cells (28) despite that prodomain-bound
BMP9 is fully active inmultiple cell types (14, 34). For the ques-
tion of whether and how the BMP prodomain could confer
latency to the GFD under certain conditions, it was recently
proposed that the pBMP9 complex could adopt both cross-
armed, latent, and open-armed, non-latent conformations (28).
Cross-armed conformation would resemble the latent TGF
structure. Integrin is a key activator of latent TGF, acting
through binding to the RGD sequence in the TGF prodomain.
However, there is no RGD sequence in the prodomain of either
BMP9 or BMP10. Whether pBMP10 or pBMP9 can adopt a
cross-armed latent conformation is still to be tested. A crystal
structure of a pBMP complex in a crossed-armed conformation
will provide the ultimate answer to this hypothesis.
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